BridgeMD
PRO-HEB.Efficacy of Propranolol for the treatment of central nervous system hemangioblastomas in von Hippel-Lindau disease: a randomized controlled clinical trial
EU CTIS ID: 2024-516241-39-00
What this study is testing
Study the effectiveness of propranolol on the growth of central nervous system hemangioblastomas in patients with von Hippel-Lindau disease.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age ≥ 18 years
- VHL patients with one or more central nervous system hemangioblastomas (HB) none of which require urgent surgical intervention (within 3 months)
- Patients who have provided written consent to participate in the study
- Affiliation with a social security scheme or dependent status
You likely can't join if
- Chronic obstructive pulmonary disease and asthma
- Sick sinus syndrome (including sinoatrial block)
- Untreated pheochromocytoma
- History of anaphylactic reaction
- In the context of primary and secondary prevention of gastrointestinal hemorrhages in cirrhotics: advanced liver failure with hyperbilirubinemia, massive ascites, hepatic encephalopathy
- Predisposition to hypoglycemia (such as after fasting or in case of abnormal response to hypoglycemia)
See the full eligibility criteria
- Age ≥ 18 years
- VHL patients with one or more central nervous system hemangioblastomas (HB) none of which require urgent surgical intervention (within 3 months)
- Patients who have provided written consent to participate in the study
- Affiliation with a social security scheme or dependent status
- Chronic obstructive pulmonary disease and asthma
- Sick sinus syndrome (including sinoatrial block)
- Untreated pheochromocytoma
- History of anaphylactic reaction
- In the context of primary and secondary prevention of gastrointestinal hemorrhages in cirrhotics: advanced liver failure with hyperbilirubinemia, massive ascites, hepatic encephalopathy
- Predisposition to hypoglycemia (such as after fasting or in case of abnormal response to hypoglycemia)
- Metabolic acidosis
- Contraindications for MRI: • Claustrophobia • Presence of a pacemaker and other stimulators/implants • Metallic foreign bodies in the eyes • Ferromagnetic cardiac valves or vascular clips • Patients already on propranolol or another beta-blocker • Patients under guardianship or conservatorship, or under judicial protection • Pregnant or breastfeeding women • Women planning a pregnancy in the medium term
- Uncontrolled heart failure
- Second- and third-degree atrioventricular blocks
- Bradycardia (<50 beats/minute after 3 minutes of rest)
- Raynaud's phenomenon and severe peripheral arterial disease
- Hypotension
- Hypersensitivity to propranolol
- Cardiogenic shock
- Prinzmetal angina
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.